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Objectives: To investigate whether it is possible to determine signs of imminent dying and change in pain
and symptom intensity during pharmacological treatment in nursing home patients, from day perceived
as dying and to day of death.
Design: Prospective, longitudinal trajectory trial.
Setting: Forty-seven nursing homes within 35 municipalities of Norway.
Participants: A total of 691 nursing home patients were followed during the ﬁrst year after admission and
152 were assessed carefully in their last days of life.
Measurements: Time between admission and day of death, and symptom severity by Edmonton symptom
assessment system (ESAS), pain (mobilization-observation-behavior-intensity-dementia-2), level of de-
mentia (clinical dementia rating scale), physical function (Karnofsky performance scale), and activities of
daily living (physical self-maintenance scale).
Results: Twenty-ﬁve percent died during the ﬁrst year after admission. Increased fatigue (logistic
regression, odds ratio [OR] 1.8, P ¼ .009) and poor appetite (OR 1.2, P ¼ .005) were signiﬁcantly associated
with being able to identify the day a person was imminently dying, which was possible in 61% of the
dying (n ¼ 82). On that day, the administration of opioids, midazolam, and anticholinergics increased
signiﬁcantly (P < .001), and was associated with amelioration of symptoms, such as pain (mixed-models
linear regression, 60% vs 46%, P < .001), anxiety (44% vs 31%, P < .001), and depression (33% vs 15%,
P < .001). However, most symptoms were still prevalent at day of death, and moderate to severe dyspnea
and death rattle increased from 44% to 53% (P ¼ .040) and 8% to 19% (P < .001), respectively. Respiratory
symptoms were not associated with opioids or anticholinergics.
Conclusion: Pharmacological treatment ameliorated distressing symptoms in dying nursing home pa-
tients; however, most symptoms, including pain and dyspnea, were still common at day of death. Results
emphasize critical needs for better implementation of guidelines and staff education.
Trial registration: ClinicalTrials.gov NCT01920100.
 2016 AMDA e The Society for Post-Acute and Long-Term Care Medicine. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).MSc, Department of Global
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and Long-Term Care Medicine. ThThe rapidly aging population, combined with substantial urban
changes in the society, makes the role of institutional care increasingly
important for the dying old. Every year, approximately 20% of all dying
UK citizens1 and almost 50% of the dying Norwegian population, die in
a nursing home.2is is an open access article under the CC BY-NC-ND license (http://creativecommons.
R.K. Sandvik et al. / JAMDA 17 (2016) 821e827822More than 80% of all nursing home patients have dementia, a
chronic, usually progressive and incurable disease, with increased
risk of neuropsychiatric symptoms and mortality.3,4 To enhance
advance care planning and end-of-life care in nursing homes, mid-
and short-term prognostication5 and pain and symptom manage-
ment are key responsibilities for the clinician.6,7 According to the
newest National Institute for Health and Care Excellence (NICE)
guidelines, Care of dying adults in the last days of life, the recognition
and weighing up of factors that may indicate that someone is
imminently dying are complex and underestimated.8 Challenges are
even more urgent in nursing home patients and people with de-
mentia.9 Mitchell et al10 demonstrated that pneumonia, repeated
episodes of fever, and eating problems increased the 6-month
mortality risk in people with dementia. In the last 3 months of
life, dyspnea, pain, and pressure ulcers were identiﬁed to be the
most common and distressing symptoms in these individuals.
However, many nursing home patients die unexpectedly and sud-
denly because signs and symptoms for prognostication of the
imminent death are not yet established, leading to increasedTable 1
Measurement Tools Used in the Study
What Does the Tool Measure? Tool Cha
ESAS Pain and distressing symptoms (fatigue, drowsiness,
nausea, appetite disturbances, dyspnea, depression,
anxiety, and well-being)
Edmonto
evaluat
scale (r
mild (0
severe
proper
demen
ESAS Pain and distressing symptoms (fatigue, drowsiness,
nausea, appetite disturbances, dyspnea, depression,
anxiety, sleep, vomiting, delirium, agitation, death
rattle, and constipation)
ESAS eva
scale (r
mild (0
severe
proper
demen
CDR Cognitive staging tool Clinical d
distribu
demen
demen
validat
KPS Functional performance status Karnofsk
rating s
KPS de
patient
MMSE Cognitive staging tool with 8 domains (orientation to
time and place, short-term recall, attention, and
calculation, long-term recall, language, repetition, and
complex commands)
Mini-me
questio
modera
(18e23
widely
reliabil
MOBID-2 Pain intensity and pain location from musculoskeletal
pain (Part 1), and pain from internal organs, head, and
skin (Part 2)
Mobiliza
demen
intensi
behavi
The 10
scale (0
observ
rated a
reliabil
PSMS Activities of daily living are assessed by 6 domains
(toileting, eating, dressing, grooming, transfer, and
bathing)
Lawton a
(PSMS)
1e5 (ra
increas
reliabil
severe
RAI-PC Distressing symptoms, care and treatment provided Resident
(RAI-PC
commu
social r
we inc
nutritiosuffering of the individual.11 A Dutch observational study reported
that identifying a patient as terminally ill was possible only when
the person died within the next 3 days.12 Patients in this study were
recognized as imminent dying by the lack of ﬂuid and nutrition
intake, general weakness, dyspnea, and somnolence. Another
nursing home study found signiﬁcant decrease of pain and dis-
tressing symptoms during the last 2 days of life, by retrospective
observation.13 Contrary to these ﬁndings, pain, agitation, and dys-
pnea were found in 6% to 71% of affected patients, in the last week
and days before death.14
Better predictability and treatment of these symptoms may
contribute to the overall end-of-life care in nursing homes, and most
recent recommendations emphasized the importance of prospective
studies in elderly patients and people with dementia.15 Few studies
have, however, assessed prospectively the change of pain and symp-
tom intensity alongside pharmacological treatment, from the day
when the patient was imminently dying and to the day of death.
We identiﬁed, prospectively, typical signs and symptoms prevalent
on the day when the patient was imminently dying and the day ofracteristics and Psychometric Properties Time Point for Measurement
n symptom assessment system (ESAS)
es subitem intensity on an 11-point Likert
ange 0e10). Intensity is grouped as none to
e2), mild to moderate (3e6), and moderate to
(7e10).37 ESAS has shown good psychometric
ties, and has been used in dying people with
tia.15e17
Baseline
luates subitem intensity on an 11-point Likert
ange 0e10). Intensity is grouped as none to
e2), mild to moderate (3e6), and moderate to
(7e10).37 ESAS has shown good psychometric
ties, and has been used in dying people with
tia.15e17
Day perceived as dying,
day of death
ementia rating (CDR) consists of 5 steps (0e3)
ted as follows: no dementia (0 and 0.5), mild
tia (1), moderate dementia (2), severe
tia (3). CDR is a reliable, valid, and feasible tool,
ed in the Norwegian language.27
Baseline
y performance status scale (KPS) is an 11-step
cale from normal function (100), to dead (0).
monstrates good psychometric properties in
s with cancer and in elderly people.21
Baseline,
day perceived as dying
ntal state examination (MMSE) is a 30-point
nnaire (0e30); severe impairment (0e11),
te impairment (12e17), mild impairment
), and no impairment (24e30). MMSE is
used and demonstrates good validity and
ity.23e26
Baseline
tion-observation-behavior-intensity-
tia-2 Pain Scale (MOBID-2) assesses pain
ty and pain location based on patient’s pain
or during standardized, guided movements.
items are scored on a 0e10 numerical rating
¼ no pain, 10 ¼ severe pain). Based on all
ations, the patient’s overall pain intensity is
gain on a 0e10 scale. MOBID-2 has excellent
ity, validity, and good responsiveness.18
Baseline,
day perceived as dying
day of death
nd Brody physical self-maintenance scale
has 6 domains, each scored on a scale from
nge 6e30). Increasing numbers means
ing dependence in daily functioning. Good
ity and validity, and sensitive to change in
dementia.19,20
Baseline
s Assessment Instrument for Palliative Care
) consists of 8 domains (symptoms,
nication, mood, functional status, preferences,
elations, spirituality, and treatments), of which
luded items for mouth care, bedsores, and
n.22
Baseline,
day perceived as dying,
day of death
Fig. 1. Study ﬂow chart for 691 patients individually admitted to 47 Norwegian nursing homes (NH) from January 2012 to June 2014.
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anticholinergics were associated with change of pain and symptom
intensity between these 2 time points.Table 2
Baseline Clinical Characteristics for Patients Admitted Individually to a Nursing
Home From January 2012 to June 2014
Characteristics Total
Sample,
n ¼ 607
Dying
Within
1 Year,
n ¼ 152
Alive 1
Year,
n ¼ 455
P*
Age, y, mean (SD) 86.3 (7.5) 86.4 (6.9) 86.3 (7.7) .944
Female, n (%) 388 (63.9) 90 (59.2) 298 (65.5) .162
KPS (0e100), mean (SD) 54.3 (28.8) 53.9 (53.9) 54.4 (14.0) .882
MMSE (0e30), mean (SD) 16.2 (6.5) 15.7 (7.0) 16.3 (6.4) .549
CDR (0, 0.5), n (%) 78 (13.3) 23 (16) 55 (12.4) .006
CDR (1), n (%) 142 (24.1) 33 (22.9) 109 (24.5)
CDR (2), n (%) 247 (41.9) 47(32.6) 200 (44.9)
CDR (3), n (%) 122 (20.7) 41 (28.5) 81 (18.2)
PSMS (6e30), mean (SD) 15.4 (0.2) 17.3 (4.8) 14.8 (4.3) <.001
MOBID-2 (0e10), mean (SD) 2.1 (0.1) 2.3 (2.3) 2.0 (2.1) .199
ESAS symptoms, mean (SD)
Pain, mean (SD) 2.6 (2.6) 3.1 (2.6) 2.5 (2.5) .044
Fatigue, mean (SD) 2.9 (2.7) 3.6 (3.1) 2.7 (2.6) .001
Drowsiness, mean (SD) 2.7 (2.7) 3.6 (2.9) 2.5 (2.5) .001
Nausea, mean (SD) 0.6 (1.6) 0.8 (1.9) 0.6 (1.5) .211
Poor appetite, mean (SD) 1.4 (2.5) 2.0 (3.0) 1.2 (2.3) .003
Dyspnea, mean (SD) 1.3 (2.2) 2.0 (2.8) 1.0 (2.0) <.001
Depression, mean (SD) 2.4 (2.6) 2.4 (1.9) 2.3 (2.6) .771
Anxiety, mean (SD) 2.2 (2.8) 2.6 (3.2) 2.1 (2.7) .088
Well-being, mean (SD) 3.0 (2.5) 3.5 (2.7) 2.9 (2.4) .019
RAI-PC items, n (%)
Problems chewing 26 (7.2) 11 (12.1) 15 (5.6) .037
Problems swallowing 28 (7.8) 12 (13.2) 16 (5.9) .025
Mouth pain 11 (3.1) 7 (7.7) 4 (1.5) .003
Nutritional problems 57 (15.8) 19 (20.9) 38 (14.1) .127
Nutritional substitute 55 (15.3) 22 (24.2) 33 (12.3) .006
Bedsore, stage 1 41 (12.4) 17 (20.7) 24 (9.6) .008
Bedsore, stage 2 52 (15.9) 24 (29.6) 28 (11.4) <.001
Bedsore, stage 3 14 (4.4) 7 (9.3) 7 (2.9) .017
Bedsore, stage 4 5 (1.6) 1 (1.3) 4 (1.7) .846
CDR, higher score indicates higher cognitive impairment; ESAS, higher scores
indicate more severe symptoms; KPS, lower scores indicate more dependence;
MMSE, lower scores indicate more cognitive impairment; PSMS, increasing
numbers indicate higher dependency.
*P value from exact c2 test for dichotomous variables and otherwise t test
comparing those who died within 1 year with those who were alive after 1 year.Methods
This was a prospective, multicenter longitudinal trajectory study
including 47 nursing homes from 35 municipalities, in 4 counties of
Norway. Between January 2012 and June 2014, eligible participants,
aged 65 years and older or younger people with an early diagnosis of
dementia, were included. They were all admitted to long-term care
units and had an expected survival of 6 weeks or more as judged by
the multidisciplinary team (responsible nursing home physician, the
responsible nurse, and the primary caregiver). Data were collected for
each patient individually, at admission to the nursing home (baseline),
at the day the personwas perceived as dying (imminent dying), and at
the day of death. In our analyses, we included only patients followed
for at least 1 year until January 1, 2015, or until death.
Registered nurses and licensed practical nurses (usually the pri-
mary caregiver) with close knowledge of the patient performed all
assessments under supervision by experienced research nurses.When
a patient was not able to give valid self-report due to dementia or
unconsciousness, the primary caregiver performed as a proxy-rater.
The assessors participated in a 2-day standardized training program
(12 hours) and received speciﬁc training in use of the instruments,
before the data collection. End-of-life carewas performed according to
standard procedures at each individual nursing home. When a patient
showed deteriorating health conditions, the multidisciplinary team
evaluated whether the individual was imminently dying by clinical
signs due to their own clinical experience. On this day and at the day of
death, data were compiled in a telephone interview between the
patient’s primary caregiver and the research nurse, including stan-
dardized measurement scales (Table 1).
Pain and distressing symptoms were assessed at baseline (T0), the
day a patient was imminently dying (T1), and the day of death (T2),
using the Edmonton symptom assessment system (ESAS) with symp-
toms of fatigue, drowsiness, nausea, poor appetite, dyspnea, depres-
sion, anxiety, and well-being.16 Six additional symptoms (sleep
disturbances, vomiting, delirium, agitation, death rattle, and con-
stipation) were also assessed at T1 and T2 (Table 1). Moderate andsevere symptoms on the ESAS scores (score 3) were regarded as
clinically signiﬁcant.17 The scale has been used and validated for proxy-
rating,18 but has not yet been used in dying patients with dementia. We
Table 3
Proportion of Patients (%) Categorized According to Severity of ESAS Symptoms in
Nursing Home Patients at Day of Imminently Dying and Day of Death
Symptoms Day of Imminently
Dying, n ¼ 82
Day of Death,
n ¼ 134
P*
% 95% CI % 95% CI
Pain, 0e10 <.001
0e2 39.7 (29.3e51.2) 54.2 (45.1e63.0)
3e6 34.6 (24.7e46.0) 32.5 (24.6e41.5)
7e10 25.6 (17.0e36.7) 13.3 (8.3e20.8)
Fatigue, 0e10 .001
0e2 1.3 (0.0e0.9) 10.6 (6.2e17.5)
3e6 17.9 (10.8e28.3) 10.5 (6.2e17.5)
7e10 80.8 (70.3e88.2) 78.9 (70.6e85.3)
Drowsiness, 0e10 <.001
0e2 2.5 (0.6e1.0) 12.2 (7.4e19.3)
3e6 19.2 (11.8e29.7) 11.4 (6.8e18.4)
7e10 78.2 (67.4e86.1) 76.4 (68.0e83.2)
Sleep quality, 0e10 <.001
0e2 50 (38.7e61.3) 61.2 (51.4e70.3)
3e6 31.6 (22.0e43.1) 19.1 (12.9e27.5)
7e10 18.4 (11.1e29.0) 19.1 (12.9e27.5)
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behavior-intensity-dementia-2 [MOBID-2]),19 activities of daily living
(physical self-maintenance scale [PSMS]),20,21 and physical function by
the Karnofsky performance scale (KPS).22 We further included the
items for nutrition, bedsores, and mouth care assessed by the resident
assessment instrument for palliative care (RAI-PC).23 Cognition and
level of dementia were assessed by mini-mental state examination
(MMSE)24e27 and clinical dementia rating scale (CDR) at T0.28 Admin-
istered pharmacological treatment and the causes of death were
collected from the patients’ medical records.
At nursing home admission, verbal and written informed consent
was obtained in direct conversations with all cognitively intact pa-
tients with sufﬁcient ability to consent. In patients lacking the ability
to consent, verbal and written informed and presumed consent was
obtained in direct conversationwith the patient (if possible) and his or
her legal guardian, usually a family member, after explaining the aims
and protocol of the study. The study was approved by the Regional
Committee for Medical and Health Research Ethics 2011/1738, and
registered at clinicaltrials.gov NCT01920100.
Continuous variables were described by means and SDs, and cat-
egorical variables by percentages of sample size and c2 square test.
The change within individuals in continuous variables was analyzed
with the paired t test. To examine differences between groups and
time points, we also built regression models for repeated measure-
ments with random effects for intercepts: linear mixed model for
continuous and multilevel logistic regression for dichotomous
outcome variables. We regarded P < .050 as signiﬁcant and P< .001 as
highly signiﬁcant. Statistical analyses were conducted with IBM SPSS
Statistics for Windows version 21.0 (IBM Corp, Armonk, NY), and
STATA/IC 13.1 (Stata Corp, College Station, TX).Nausea, 0e10 <.001
0e2 75.6 (64.7,84.0) 87.7 (80.5e92.3)
3e6 19.2 (11.8e29.7) 6.6 (3.2e12.7)
7e10 5.1 (1.9e13.1) 5.7 (2.7e11.7)
Vomiting, 0e10 <.001
0e2 84.6 (74.6e91.2) 90.2 (83.5e94.4)
3e6 10.2 (5.1e19.4) 5.7 (2.7e11.6)
7e10 5.1 (1.9e13.1) 4.1 (1.7e9.5)
Poor appetite, 0e10 <.001
0e2 5.2 (1.9e13.3) 21.7 (15.4e30.3)
3e6 6.5 (2.7e14.9) 9.6 (5.3e16.6)
7e10 88.3 (78.8e93.9) 68.7 (59.5e76.6)
Dyspnea, 0e10 .040
0e2 56.6 (45.0e67.5) 47.1 (38.3e56.1)
3e6 22.4 (14.2e33.4) 24.0 (17.1e32.5)
7e10 21.1 (13.2e31.9) 29.0 (21.5e38.0)
Depression, 0e10 <.001
0e2 66.7 (55.0e76.6) 84.9 (77.1e90.3)
3e6 16.0 (9.2e26.4) 8.4 (4.5e15.0)
7e10 17.3 (10.2e27.9) 6.7 (3.3e13.0)
Anxiety, 0e10 <.001
0e2 55.8 (44.4e66.7) 69.1 (60.3e76.7)
3e6 24.7 (16.2e35.8) 15.4 (10.0e23.1)
7e10 19.5 (12.0e30.1) 15.4 (10.0e23.1)
Delirium, 0e10 <.001Results
In all, 691 patients from 47 Norwegian nursing homes were
included for the baseline assessment (T0). Forty-seven patients were
excluded from further follow-up testing because they moved home or
to other institutions or declined to participate (Figure 1). To avoid
noninformative censoring, we also excluded 37 patients with nursing
home stay less than 1 year. This left 607 patients for the follow-up
analyses, of whom 369 (63%) had moderate to severe dementia ac-
cording to the CDR scale (Table 2). A total of 152 patients (25%) died
during the ﬁrst year; of those, 18 were excluded from our analyses
because of missing data (Figure 1). The remaining 134 patients were
all assessed on their day of death (T2). For 82 patients (61%), the
multidisciplinary team identiﬁed the day of imminent dying (T1),
whereas 52 patients were not recognized as dying, in advance. Thus,
our analyses comprised 82 patients at T1 and 134 at T2. The median
number of days between T1 and T2 was 3 (range 0e73); 63% died
between day 0 and 2, 21% died between days 3 and 7, and 15% died on
day 8 or more.0e2 84.0 (73.6e90.8) 91.1 (84.4e95.0)
3e6 8.0 (3.6e16.9) 2.4 (3.3e12.6)
7e10 8.0 (3.6e17.0) 0.7 (0.1e0.7)
Agitation, 0e10 <.001
0e2 90.8 (81.6e95.6) 96.7 (91.5e98.8)
3e6 6.6 (2.7e15.1) 2.4 (0.1e0.7)
7e10 2.6 (0.6e10.2) 0.8 (0.1e5.7)
Death rattle, 0e10 <.001
0e2 92.3 (83.7e96.6) 81.5 (73.5e87.4)
3e6 5.1 (1.8e13.1) 10.4 (6.1e17.3)
7e10 2.6 (0.6e10.0) 8.1 (4.4e14.5)
Constipation, 0e10 <.001
0e2 75.6 (64.7e84.0) 91.8 (85.3e95.6)
3e6 20.5 (12.8e31.2) 7.3 (3.8e13.7)
7e10 3.5 (1.2e11.5) 0.8 (0.1e5.7)
*Mixed-models linear regression symptom as dependent variable and time as
independent variablePredictors for 1-Year Mortality
Patients (n ¼ 152, 25%) who died during the ﬁrst year had more
dyspnea (P < .001), drowsiness (P ¼ .001), fatigue (P ¼ .001), pain
(P ¼ .044), and dependency in daily activities (P < .001) at admission
(T0), and experienced less well-being (P ¼ .019) and appetite
(P ¼ .003), compared with those who were still alive after 1 year
(n ¼ 455) (Table 2). These patients had also more chewing and
swallowing problems (P ¼ .037, P ¼ .025, respectively), pain in the
mouth (P ¼ .003), nutritional substitution (P ¼ .006), and bedsores
stage 1, 2, and 3 (P ¼ .008, P < .001, and P ¼ .017, respectively). Di-
agnoses of death suggested that 21% died of pneumonia, followed by
heart failure (18%), dementia (15%), stroke (15%), and cancer (7%) orkidney failure (7%). In 17% of the patients, diagnoses of death were
missing for administrative reasons.
Signs and Symptoms of Imminent Dying (T1)
Shown in Table 3, fatigue (99%), drowsiness (98%), and reduced
appetite (95%) were the most frequently observed ESAS symptoms
with moderate to severe intensity at T1. Moderate to severe pain
assessed with ESASwas found in 60% of the patients, highly correlated
Table 4
Proportion of Patients (%) by Administered Analgesic Drugs at Day of Imminently
Dying and Day of Death
Drugs Day of Imminently
Dying, n ¼ 82
Day of Death,
n ¼ 134
P*
% 95% CI % 95% CI
Paracetamol 51.9 40.8e62.7 35.1 27.4e43.6 .445
Weak opioidsy 3.7 1.2e11.1 37.3 29.5e45.9 <.001
Strong opioidsz 48.1 37.3e59.2 65.7 57.1e73.3 <.001
Benzodiazepines 23.5 15.3e34.1 13.4 8.6e20.4 .841
Midazolam 8.6 4.1e17.3 17.2 11.6e24.6 <.001
Antiemetics 1.2 1.2e8.5 3.0 1.1e7.8 .174
Anticholinergicsx 6.2 2.5e14.2 18.6 12.9e26.3 <.001
Haloperidol 6.2 2.5e14.2 6.0 3.0e11.6 .255
*Mixed-models linear regression symptom as dependent variable and time as
independent variable not P value from exact c2 test.
yCodeine, tramadol.
zMorphine, fentanyl, oxycodone, buprenorphine.
xGlycopyrronium bromide, morphine-scopolamine, scopolamine.
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relation 0.618, P < .001). Moderate to severe degree of sleep distur-
bances (50%), anxiety (44%), dyspnea (44%), and depression (33%)
were also common at T1.
We entered the variable identiﬁed/not identiﬁed as imminently
dying into logistic regression analyses with all ESAS symptoms at day of
death. We found that increased fatigue (odds ratio [OR] 1.8, 95% con-
ﬁdence interval [CI] 1.16e2.85, P¼ .009) and poor appetite (OR 1.2, 95%
CI 1.06e1.41, P ¼ .005) were signiﬁcantly associated with being able to
identify the day a person was imminently dying; however, symptoms
of pain or dyspnea did not contribute to the recognition of imminent
dying, and the presence of deliriumwas associated with not being able
to identify a person as dying at T1 (OR 0.6, 95%CI 0.4e0.9, P ¼ .010).Pain and Symptom Intensity at Day of Death (T2)
Moderate and severe degree of fatigue (89%), drowsiness (88%),
and reduced appetite (78%) were still most frequently observed at T2
(Table 3). We found a proportional amelioration in patients with pain
(60% vs 46%, P < .001), anxiety (44% vs 31%, P < .001), depression (33%
vs 15%, P < .001), nausea (24% vs 12%, P < .001), constipation (24% vs
8%, P < .001), and delirium (16% vs 3.1%, P < .001) from T1 to T2.
Dyspnea was frequently observed in the patients, and increased from
44% to 53% (P ¼ .040). The proportion of patients with death rattle
increased from 8% to 19% (P < .001) (Table 3). Between T1 and T2, the
prevalence of agitation and delirium together decreased from 28% to
19% (P < .001). Patients who in advance were identiﬁed as dying
(n¼ 82, 61%) showed signiﬁcantly more fatigue (P< .001), drowsiness
(P ¼ .006), and loss of appetite (P < .001) compared with those who
died unexpectedly (n ¼ 52, 39%).Table 5
Change in ESAS Symptom Severity Between the Day of Imminently Dying and the Day o
Treatment
Symptoms
Opioids, *n ¼ 58 Anxiolytics/s
b 95% CI P b
Pain 1.04 (2.03 to 0.04) .041 1.00
Nausea 0.82 (1.59 to 0.58) .035 0.92
Death rattle 1.05 (0.20 to 1.91) .016 1.96
Dyspnea 0.60 (0.66 to 1 to 86) .350 2.54
Agitation 1.13 (1.85 to 0.41) .002 0.27
Anxiety 1.18 (2.41 to 0.04) .058 0.80
Only patients who newly started with the treatment were included in these analyses. Inve
variables.
*Codeine, tramadol, morphine, fentanyl, oxycodone, buprenorphine.
yBenzodiazepines (including midazolam).
zScopolamine, morphine-scopolamine, glycopyrronium bromide.Pain and Symptom Management in the Last Days and Hours of Life
Paracetamol was the most frequently used drug (52%) on day of
imminent dying. The administration of strong opioids increased from
48% to 66% (P < .001) and weak opioids increased from 4% to 37%
(P < .001) between T1 and T2. The use of midazolam doubled from 9%
to 17% (P< .001), whereas anxiolytics, in general, were stable with 29%
at T1 and 30% at T2 (P ¼ .781). Anticholinergic drug prescription
increased from 6% to 19% (P < .001), and antiemetics decreased from
15% to 10% (P ¼ .008) (Table 4). The linear mixed-models regression
analyses investigated changes in ESAS symptom scores only in pa-
tients (n ¼ 75) who started pharmacological treatment between T1
and T2 (Table 5). The initiation of opioids was associated with reduced
pain intensity (P ¼ .041), nausea (P ¼ .035), death rattle (P ¼ .016), and
agitation (P¼ .002), but not dyspnea (P ¼ .350). The use of anxiolytics/
sedatives was associated with the reduction of nausea (P ¼ .031),
agitation (P ¼ .015), death rattle (P ¼ .011), and dyspnea (P ¼ .007).
Finally, anticholinergics were associated with reduced anxiety
(P ¼ .012) and agitation (P < .001) but not death rattle.
Discussion
This study found that 1 in 4 patients died during the ﬁrst year after
nursing home admission, most often with diagnoses of pneumonia,
heart failure, and dementia. The day of imminent dying was identiﬁed
in 61% by fatigue and poor appetite. In the last days of life, the
administration of opioids, midazolam, and anticholinergics increased
signiﬁcantly and was associated with the amelioration of symptoms
such as pain, anxiety, and depression.
This was, to our knowledge, the ﬁrst study that prospectively
assessed the change of pain and symptom intensity between the day of
imminent dying (T1) and the day of death (T2). Alarming ﬁndings un-
covered the high number of patients who still experienced dyspnea
(53%), pain (46%), sleep problems (40%), and anxiety (31%) at T2.
Moreover, the prevalence of death rattle increased from 8% to 19%.
Compared with other studies,11,14 agitation and delirium were less
frequently observed at the end of life. It is uncertain, however, whether
amelioration of agitated symptomswas related only to the treatmentof
pain or increased physical weakness over time.11 A possible under-
detection of deliriummight limit our results, as we did not include any
speciﬁc tool assessing this disease by a valid delirium tool, such as the
Confusion Assessment Method.29 Although the administration of opi-
oids increased from 44% to 66% betweenT1 and T2 in our study, ﬁgures
were lower in a comparable study inwhich all patients (100%) received
morphine (in mean 30 mg per day).11 Nuanced interpretation of these
results is required because the use of morphine, as a “one-size-ﬁts-all”
solution, doesnotnecessarilyguaranteegood treatment. Tovalidate the
efﬁcacy, it is a prerequisite to assess pain and symptom intensity before
and after symptommanagement has been initiated.30f Death
edatives, yn ¼ 27 Anticholinergic drugs, zn ¼ 24
95% CI P b 95% CI P
(2.50 to 0.54) .206 1.45 (3.02 to 0.12) .071
(1.76 to 0.08) .031 1.25 (2.53 to 0.41) .058
(0.45 to 3.47) .011 1.01 (0.05 to 2.08) .063
(0.71 to 4.37) .007 0.15 (1.74 to 2.03) .878
(2.29 to 0.25) .015 2.12 (3.23 to 0.90) .001
(2.90 to 1.29) .451 2.49 (4.44 to 0.55) .012
stigated with linear mixed-models regression analysis; ESAS subitems as dependent
R.K. Sandvik et al. / JAMDA 17 (2016) 821e827826In the present and also other studies,11,13,14 the most prevalent
distressing symptomwas dyspnea (53%), complicated by its subjective
burden with multiple potential etiologies, such as pneumonia and
lung edema in connection to heart failure.14,31 Although the exact
mode of action of opioids in dyspnea management is unknown, pe-
ripheral and central mechanisms have earlier been postulated.32 Thus,
it was an unexpected ﬁnding that opioids were not associated with
reduction of the dyspnea intensity scores in our study. Although it is
widely held that glycopyrrolate and scopolamine subcutaneously are
useful treatments of death rattle in patients with cancer,33 it may be
difﬁcult for nursing home staff to distinguish between death rattle and
sounds of accumulating secretion in connection with pneumonia or
heart failure with lung edema.34 Diagnostic challenges also may be
apparent for nausea in connection with newly started opioids in
peoplewho are no longer able to describe their suffering. Caregivers in
our study observed nausea in only a very few patients; other studies
did not mention this symptom.10,11,14
Although it is broadly believed that the identiﬁcation of imminent
dying is a hallmark to initiate end-of-life care, the frequency and
severity of typical symptoms have not yet been described.5,35 In the
present study, nursing home staff identiﬁed T1 in 61% of their patients,
through changes in fatigue and poor appetite. Symptoms such as pain,
dyspnea, or agitation did not predict imminent death. This is note-
worthy because physical symptoms of weakness do not explain the
initiation of pharmacological treatment. It is possible that the di-
agnoses of death (pneumonia, heart failure, and dementia) are trigger
factors for increased pain, dyspnea, and anxiety. Interestingly, the
prevalence of pain was not associated with agitation in our study,
although individual pain treatment has been demonstrated to be
correlated to the reduction of pain and agitation.13,36e38 Compared
with younger patients with cancer, the timely prognostication of
death is challenging due to the patient’s deterioration over a long time
period.35 Our ﬁndings should be used to enhance staff education in
care of dying nursing home patients because these symptoms are
challenging to distinguish: a prerequisite to provide proper symptom
management. Although Norwegian authorities are developing a sub-
specialization for nursing home physicians and a master’s degree for
geriatric nursing, these standards are not yet established. Regular
training and education of nursing home staff andmedical students are
priorities, but skills and competence regarding end-of-life care in
people with dementia vary considerably among institutions.
Limitations and Strengths
Our study used the continuous measures of ESAS symptom scores,
which to our knowledge are not validated in dying people with de-
mentia. ESAS has previously been used in the nursing home setting and
is the only end-of-life care instrument with relevant symptom list to
assess change in symptom intensity during treatment by a continuous
scale.13,39 However, the validity of proxy-rated intensity scores may
always be questionable in dying patients and people with dementia. A
further limitation is the lack of instruments to assess the quality of life
and quality of death and dying, which is an important consideration for
future studies. Additionally, to improve the situation for the dying old,
we would also recommend exploring convenient nonpharmacological
interventions, such as fresh air in the case of dyspnea. Beneﬁcially, our
sample size at baseline was larger than comparable studies.10e14
However, when we assessed the association between newly initiated
pharmacological treatment and changes in pain and symptom intensity
we ended up with a rather low sample of 75 people.
Conclusion
In the present study, pain and symptom management were asso-
ciated with symptom relief in dying nursing home patients.Nevertheless, too many people still experienced unacceptably high
levels of pain and distressing symptoms in the last days of life, which
emphasizes the critical need for user-speciﬁc guidelines, better
implementation, and staff education in nursing homes.Acknowledgment
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